文献速递中枢神经肿瘤放疗姑息放疗与转移瘤

脑转移对颅外寡转移患者分类、治疗及结局的影响:单中心横断面分析

Influence of brain metastases on the classification, treatment, and outcome of patients with extracranial oligometastasis: a single-center cross-sectional analysis.
PubMed 文献 · Radiat Oncol · 2024-10-27

该单中心横断面分析基于7000次肿瘤正电子发射断层扫描,识别出106例颅外寡转移合并脑转移患者,脑转移使45%患者从颅外寡转移转为全身多转移状态;寡转移亚组中位总生存28个月,多转移亚组10个月(p<0.01)。

要点

  • 脑转移导致45%(n=48)患者从颅外寡转移转为全身多转移状态。
  • 寡转移亚组中位总生存28个月,多转移亚组10个月(p<0.01)。
  • 脑转移不应作为寡转移疾病临床试验的排除标准。

核心结论

  • 在脑转移患者中,低总体肿瘤负荷的寡转移疾病状态仍是总生存的显著预后因素。
  • 脑转移不应作为寡转移疾病领域临床试验的排除标准。
  • 强调在寡转移癌症患者中考虑多模态治疗策略的重要性。

研究设计与样本

  • 单中心横断面分析,分析7000次肿瘤正电子发射断层扫描以识别颅外寡转移疾病患者(定义为≤5个颅内或颅外转移灶)。
  • 评估同期脑磁共振成像以量化颅内肿瘤负荷,并采用回归分析评估从寡转移向多转移状态转变的预测因素。

主要发现

  • 共识别106例颅外寡转移合并同时性脑转移患者,主要原发肿瘤为皮肤或肺/胸膜癌(90%,n=96)。
  • 脑转移导致45%(n=48)患者从颅外寡转移转为全身多转移状态。
  • 寡转移患者接受全身治疗更频繁(55% vs 35%),多转移患者更常接受脑转移放疗(44% vs 26%),但两亚组间治疗方法无系统性差异。
  • 寡转移亚组中位总生存28个月,多转移亚组10个月(p<0.01)。

临床怎么用

  • 作者认为脑转移不应作为寡转移疾病临床试验的排除标准。
  • 作者强调在寡转移癌症患者中考虑多模态治疗策略的重要性。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND AND INTRODUCTION: Increasing evidence suggests that a subgroup of patients with oligometastatic cancer might achieve a prolonged disease-free survival through local therapy for all active cancer lesions. Our aims are to investigate the impact of brain metastases on the classification, treatment, and outcome in these patients. MATERIALS AND METHODS: We analyzed a total of 7,000 oncological positron emission tomography scans to identify patients with extracranial oligometastatic disease (defined as ≤ 5 intra- or extra-cranial metastases). Concurrent magnetic resonance imaging brain was assessed to quantify intracranial tumor burden. We investigated the impact of brain metastases on oligometastatic disease state, therapeutic approaches, and outcome. Predictors for transitioning from oligo- to polymetastatic states were evaluated using regression analysis. RESULTS: A total of 106 patients with extracranial oligometastases and simultaneous brain metastases were identified, primarily originating from skin or lung/pleura cancers (90%, n = 96). Brain metastases caused a transition from an extracranial oligometastatic to a whole-body polymetastatic state in 45% (n = 48) of patients. While oligometastatic patients received systemic therapy (55% vs. 35%) more frequently and radiotherapy for brain metastases was more often prescribed to polymetastatic patients (44% vs. 26%), the therapeutic approach did not differ systematically between both sub-groups. The oligometastatic sub-group had a median overall survival of 28 months compared to 10 months in the polymetastatic sub-group (p < 0.01). CONCLUSION: In patients with brain metastases, a low total tumor burden with an oligometastatic disease state remained a significant prognostic factor for overall survival. Presence of brain metastases should therefore not serve as exclusion criterion for clinical trials in the field of oligometastatic disease. Moreover, it underscores the importance of considering a multimodality treatment strategy in oligometastatic cancer patients.

来源:Radiat Oncol,查看原文。版权归原作者所有。

引用

  1. Christ SM, Thiel GW, Heesen P, et al. Influence of brain metastases on the classification, treatment, and outcome of patients with extracranial oligometastasis: a single-center cross-sectional analysis. Radiat Oncol. 2024. PMID: 39465396. doi:10.1186/s13014-024-02542-2

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。